{"id":647596,"date":"2013-03-19T16:53:02","date_gmt":"2013-03-19T20:53:02","guid":{"rendered":"http:\/\/www.pehub.com\/?p=191826"},"modified":"2013-03-19T16:53:02","modified_gmt":"2013-03-19T20:53:02","slug":"dc-devices-raises-9m-from-canadian-u-s-vc-funds","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/647596","title":{"rendered":"DC Devices Raises $9M from Canadian & U.S. VC Funds"},"content":{"rendered":"

\"\"<\/a>DC Devices Inc. <\/strong>has\u00a0raised US$9 Million from a consortium of investors. Lumira Capital<\/strong> joined the financing along with existing\u00a0investors Third Rock Ventures<\/strong> and General Catalyst<\/strong>. Gerry Brunk<\/strong>, managing director of\u00a0Lumira, joined the company’s board of directors.\u00a0Tewksbury, Mass.-based DC Devices, a medical device company for the treatment of congestive heart failure, has been venture-backed since 2009.<\/p>\n

PRESS RELEASE:<\/strong><\/p>\n

DC Devices Inc., an innovative medical device\u00a0company developing first-in-class structural heart devices, today announced that it has secured\u00a0$9 million in financing. Lumira Capital joined the financing along with the company’s existing\u00a0investors Third Rock Ventures and General Catalyst, and Gerry Brunk, managing director of\u00a0Lumira Capital, has joined the DC Devices board of directors. This financing will support DC\u00a0Devices’ accelerated development and ongoing clinical evaluation of the first trans-catheter<\/p>\n

device for the treatment of diastolic heart failure (DHF), also known as heart failure with\u00a0preserved ejection fraction (HFpEF).<\/p>\n

“Patients suffering from diastolic heart failure have no effective treatment options today, and a\u00a0mortality rate that rivals that of cancer,” said Mr. Brunk. “With heart failure representing the\u00a0single largest cause of hospitalizations in many countries, and the largest cost line item in the\u00a0U.S. Medicare budget, new therapies are desperately needed. We’re very excited to support the\u00a0DC Devices team in its effort to bring a potentially transformative new therapy to patients.”<\/p>\n

DC Devices’ proprietary, minimally invasive InterAtrial Shunt Device (IASD\u2122) system is the\u00a0first device intended to treat DHF\/HFpEF. The IASD system works to relieve increased left atrial\u00a0pressure, the main cause of DHF\/HFpEF symptoms, by placing a permanent implant in the atrial\u00a0septum designed to reduce the elevated pressure and relieve symptoms. The innovative IASD\u00a0system allows physicians to perform this trans-catheter treatment without open-heart surgery and
\nin a controlled fashion using standard interventional cardiology techniques.<\/p>\n

“This is an exciting time of growth and progress for DC Devices, as we have completed our firstin-human safety studies and are currently enrolling a European pilot trial for our proprietary\u00a0IASD system,” said George Fazio, president and chief executive officer of DC Devices. “We\u00a0expect to make rapid advances this year, as we work toward our goal of developing a new,\u00a0minimally-invasive and permanent device for the treatment of DHF\/HFpEF that is designed to be\u00a0cost-effective, and could dramatically improve patients’ quality of life while significantly\u00a0reducing hospitalization costs.”<\/p>\n

Mr. Brunk joins the current DC Devices board of directors, which includes: David Celermajer,\u00a0M.D., co-founder, DC Devices; George Fazio, chief executive officer, DC Devices; Paul LaViolette, partner, SV Life Sciences, who serves as chairman; Mark Levin, partner, Third Rock\u00a0Ventures; and Hemant Taneja, managing director, General Catalyst.<\/p>\n

About DC Devices\u00a0<\/strong><\/p>\n

DC Devices is dedicated to revolutionizing the treatment of heart failure with first-in-class\u00a0structural heart devices. The company is developing the first trans-catheter device for diastolic\u00a0heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It<\/p>\n

 <\/p>\n

s\u00a0proprietary and innovative InterAtrial Shunt Device (IASD\u2122) system is minimally invasive and\u00a0is designed to relieve increased left atrial pressure (LAp), the main cause of DHF\/HFpEF\u00a0symptoms. The IASD system is designed to be cost-effective and is intended to dramatically\u00a0improve patients’ quality of life while significantly reducing hospitalization costs. The IASD\u00a0System is currently under clinical investigation outside the U.S., and is not available in the U.S.\u00a0for investigational use or commercial distribution. Founded by experienced and proven leaders in\u00a0the interventional cardiology space and medical device industry, DC Devices is funded by\u00a0leading investors Third Rock Ventures, General Catalyst and Lumira Capital. The company is\u00a0headquartered in Tewksbury, Mass. For more information, please visit www.dcdevicesinc.com.<\/p>\n

Photo courtest of Shutterstock.<\/p>\n

The post DC Devices Raises $9M from Canadian & U.S. VC Funds<\/a> appeared first on peHUB<\/a>.<\/p>\n

\n<\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

DC Devices Inc. has\u00a0raised US$9 Million from a consortium of investors. Lumira Capital joined the financing along with existing\u00a0investors Third Rock Ventures and General Catalyst. Gerry Brunk, managing director of\u00a0Lumira, joined the company’s board of directors.\u00a0Tewksbury, Mass.-based DC Devices, a medical device company for the treatment of congestive heart failure, has been venture-backed since 2009. […]<\/p>\n","protected":false},"author":7824,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-647596","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/647596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/7824"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=647596"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/647596\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=647596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=647596"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=647596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}